Key result
Repeated desmopressin (DDAVP) infusions yielded consistent responses, with 80% of vWD patients and nearly 70% of hemophilia A patients showing <20% departure from average VIII:C peak levels.
Why the study?
Does repeated desmopressin (DDAVP) infusion produce consistent VIII:C peak levels and bleeding times in patients with von Willebrand's disease and hemophilia A?
Population
32 patients, including 22 with von Willebrand's disease (vWD) and 10 with mild or moderate hemophilia A.
Design
Cohort
Follow-up
median 13 months between first and last infusion
Authors
Loading...
Supports initial DDAVP test dosing to guide repeat use in vWD and hemophilia A; leaves open need for prospective validation.
Observational (n=32)
Does repeated desmopressin (DDAVP) infusion produce consistent VIII:C peak levels and bleeding times in patients with von Willebrand's disease and hemophilia A?
The pattern of responsiveness observed after an initial DDAVP test-infusion is consistent over time and within families, making it a reliable guide for future clinical management.
Rodeghiero et al. (1989) conducted an observational in von Willebrand's disease and mild or moderate hemophilia A (n=32). Repeated desmopressin (DDAVP) infusions was evaluated on Consistency of VIII:C peak level and bleeding times after repeated infusions. Repeated desmopressin (DDAVP) infusions yielded consistent responses, with 80% of vWD patients and nearly 70% of hemophilia A patients showing <20% departure from average VIII:C peak levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: